Risk of diabetes among patients receiving primary androgen deprivation therapy for clinically localized prostate cancer

Journal of Urology

Volumn 193, Issue 6, 2015, Pages 1956-1962

  Tsai, Huei Ting ^a   Keating, Nancy L ^b   Van Den Eeden, Stephen K ^e   Haque, Reina ^f   Cassidy Bushrow, Andrea E ^g   Ulcickas Yood, Marianne ^c   Smith, Matthew R ^d   Potosky, Arnold L ^a  

^a GEORGETOWN UNIVERSITY   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c BOSTON UNIVERSITY SCHOOL OF PUBLIC HEALTH   (United States)

^d MASSACHUSETTS GENERAL HOSPITAL   (United States)

^e DIVISION OF RESEARCH   (United States)

^f KAISER PERMANENTE   (United States)

^g HENRY FORD HOSPITAL   (United States)

Author keywords

androgens; diabetes mellitus; prostatic neoplasms; risk

Indexed keywords

HEMOGLOBIN A1C; ANTIANDROGEN; GONADORELIN;

ADULT; AGED; ANDROGEN DEPRIVATION THERAPY; ARTICLE; CANCER RECURRENCE; COHORT ANALYSIS; DIABETES MELLITUS; DISEASE ASSOCIATION; FOLLOW UP; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; OBESITY; PRIORITY JOURNAL; PROSTATE CANCER; RETROSPECTIVE STUDY; SENSITIVITY ANALYSIS; VERY ELDERLY; ANALOGS AND DERIVATIVES; ANTAGONISTS AND INHIBITORS; CHEMICALLY INDUCED; MIDDLE AGED; PROSTATIC NEOPLASMS; RISK;

ADULT; AGED; AGED, 80 AND OVER; ANDROGEN ANTAGONISTS; COHORT STUDIES; DIABETES MELLITUS; GONADOTROPIN-RELEASING HORMONE; HUMANS; MALE; MIDDLE AGED; PROSTATIC NEOPLASMS; RETROSPECTIVE STUDIES; RISK;

EID: 84929284098     PISSN: 00225347     EISSN: 15273792     Source Type: Journal    
DOI: 10.1016/j.juro.2014.12.027     Document Type: Article

References (29)

1. National Cancer Institute (NCI): Prostate Cancer. Available at http://www.cancer.gov/cancertopics/types/prostate. Accessed October 6, 2014.
2. E.M. Messing, J. Manola, and M. Sarosdy Immediate hormonal therapy compared with observation after radical prostatectomy and pelvic lymphadenectomy in men with node-positive prostate cancer N Engl J Med 341 1999 1781
3. M. Bolla, G. Van Tienhoven, and P. Warde External irradiation with or without long-term androgen suppression for prostate cancer with high metastatic risk: 10-year results of an EORTC randomised study Lancet Oncol 11 2010 1066
4. J.W. Denham, A. Steigler, and D.S. Lamb Short-term neoadjuvant androgen deprivation and radiotherapy for locally advanced prostate cancer: 10-year data from the TROG 96.01 randomised trial Lancet Oncol 12 2011 451
5. G.L. Lu-Yao, P.C. Albertsen, and D.F. Moore Survival following primary androgen deprivation therapy among men with localized prostate cancer JAMA 300 2008 173
6. U.E. Studer, P. Whelan, and W. Albrecht Immediate or deferred androgen deprivation for patients with prostate cancer not suitable for local treatment with curative intent: European Organisation for Research and Treatment of Cancer (EORTC) Trial 30891 J Clin Oncol 24 2006 1868
7. M.R. Smith, H. Lee, and D.M. Nathan Insulin sensitivity during combined androgen blockade for prostate cancer J Clin Endocrinol Metab 91 2006 1305
8. M.R. Smith, J.S. Finkelstein, and F.J. McGovern Changes in body composition during androgen deprivation therapy for prostate cancer J Clin Endocrinol Metab 87 2002 599
9. P.J. Saylor, and M.R. Smith Metabolic complications of androgen deprivation therapy for prostate cancer J Urol 189 suppl. 2013 S34
10. N.L. Keating, A.J. O'Malley, and M.R. Smith Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer J Clin Oncol 24 2006 4448
11. M.J. Lage, B.L. Barber, and R.A. Markus Association between androgen-deprivation therapy and incidence of diabetes among males with prostate cancer Urology 70 2007 1104
12. N.L. Keating, A.J. O'Malley, and S.J. Freedland Diabetes and cardiovascular disease during androgen deprivation therapy: observational study of veterans with prostate cancer J Natl Cancer Inst 102 2010 39
13. J.M. Underwood, J.S. Townsend, and S.L. Stewart Surveillance of demographic characteristics and health behaviors among adult cancer survivors-Behavioral Risk Factor Surveillance System, United States, 2009 MMWR Surveill Summ 61 2012 1
14. E.H. Wagner, S.M. Greene, and G. Hart Building a research consortium of large health systems: the Cancer Research Network J Natl Cancer Inst Monogr 35 2005 3
15. A.L. Potosky, R. Haque, and A.E. Cassidy-Bushrow Effectiveness of primary androgen-deprivation therapy for clinically localized prostate cancer J Clin Oncol 32 2014 1324
16. American Joint Committee on Cancer: Cancer Staging References. Available at https://cancerstaging.org/references-tools/Pages/What-is-Cancer-Staging.aspx. Accessed October 6, 2014.
17. B. Kowall, and W. Rathmann HbA1c for diagnosis of type 2 diabetes. Is there an optimal cut point to assess high risk of diabetes complications, and how well does the 6.5% cutoff perform? Diabetes Metab Syndr Obes 6 2013 477
18. I. Thompson, J.B. Thrasher, and G. Aus Guideline for the management of clinically localized prostate cancer: 2007 update J Urol 177 2007 2106
19. J.E. Bekelman, G. Suneja, and T. Guzzo Effect of practice integration between urologists and radiation oncologists on prostate cancer treatment patterns J Urol 190 2013 97
20. E. Morales-Villegas Dyslipidemia, hypertension and diabetes metaflammation. A unique mechanism for 3 risk factors Curr Hypertens Rev 2014 Epub ahead of print
21. T. Kurth, A.M. Walker, and R.J. Glynn Results of multivariable logistic regression, propensity matching, propensity adjustment, and propensity-based weighting under conditions of nonuniform effect Am J Epidemiol 163 2006 262
22. J.E. Faris, and M.R. Smith Metabolic sequelae associated with androgen deprivation therapy for prostate cancer Curr Opin Endocrinol Diabetes Obes 17 2010 240
23. S. Shahani, M. Braga-Basaria, and S. Basaria Androgen deprivation therapy in prostate cancer and metabolic risk for atherosclerosis J Clin Endocrinol Metab 93 2008 2042
24. C. Allan, V.R. Collins, and M. Frydenberg Androgen deprivation therapy complications Endocr Relat Cancer 21 2014 T119
25. N.L. Keating, A. O'Malley, and S.J. Freedland Diabetes and cardiovascular disease during androgen deprivation therapy: observational study of veterans with prostate cancer J Natl Cancer Inst 104 2012 1518
26. N.L. Keating, A.J. O'Malley, and S.J. Freedland Does comorbidity influence the risk of myocardial infarction or diabetes during androgen-deprivation therapy for prostate cancer? Eur Urol 64 2013 159
27. Standards of medical care in diabetes-2014 Diabetes Care 37 suppl. 2014 S14
28. P.J. Saylor, N.L. Keating, and M.R. Smith Prostate cancer survivorship: prevention and treatment of the adverse effects of androgen deprivation therapy J Gen Intern Med 24 suppl. 2009 S389
29. N.L. Keating, P.H. Liu, and A.J. O'Malley Androgen-deprivation therapy and diabetes control among diabetic men with prostate cancer Eur Urol 65 2014 816